PharmaCyte Biotech Inc (PMCB) - Net Assets
Based on the latest financial reports, PharmaCyte Biotech Inc (PMCB) has net assets worth $34.98 Million USD as of April 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($46.75 Million) and total liabilities ($11.77 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check PharmaCyte Biotech Inc PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $34.98 Million |
| % of Total Assets | 74.82% |
| Annual Growth Rate | N/A |
| 5-Year Change | -61.1% |
| 10-Year Change | 332.54% |
| Growth Volatility | 309.36 |
PharmaCyte Biotech Inc - Net Assets Trend (2004–2026)
This chart illustrates how PharmaCyte Biotech Inc's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see market value of PharmaCyte Biotech Inc.
Annual Net Assets for PharmaCyte Biotech Inc (2004–2026)
The table below shows the annual net assets of PharmaCyte Biotech Inc from 2004 to 2026. Also explore PMCB net assets growth trend to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2026-04-30 | $34.98 Million | -32.59% |
| 2025-04-30 | $51.89 Million | +31.32% |
| 2024-04-30 | $39.51 Million | -45.64% |
| 2023-04-30 | $72.69 Million | -19.16% |
| 2022-04-30 | $89.92 Million | +1246.21% |
| 2021-04-30 | $6.68 Million | +31.25% |
| 2020-04-30 | $5.09 Million | +0.98% |
| 2019-04-30 | $5.04 Million | -12.64% |
| 2018-04-30 | $5.77 Million | -28.67% |
| 2017-04-30 | $8.09 Million | +23.99% |
| 2016-04-30 | $6.52 Million | +9.88% |
| 2015-04-30 | $5.94 Million | -33.62% |
| 2014-04-30 | $8.94 Million | +1070.46% |
| 2013-04-30 | $-921.46K | +45.79% |
| 2012-04-30 | $-1.70 Million | +37.72% |
| 2011-04-30 | $-2.73 Million | -39.88% |
| 2010-04-30 | $-1.95 Million | -162.47% |
| 2009-04-30 | $3.12 Million | -57.99% |
| 2008-04-30 | $7.44 Million | +73.48% |
| 2007-04-30 | $4.29 Million | -2.85% |
| 2006-04-30 | $4.41 Million | +440.66% |
| 2005-04-30 | $-1.30 Million | -744.12% |
| 2004-04-30 | $-153.43K | -- |
Equity Component Analysis
This analysis shows how different components contribute to PharmaCyte Biotech Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 10378009300.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (April 2026)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $2.60K | 0.01% |
| Other Comprehensive Income | $-20.80K | -0.06% |
| Other Components | $137.71 Million | 413.60% |
| Total Equity | $33.29 Million | 100.00% |
PharmaCyte Biotech Inc Competitors by Market Cap
The table below lists competitors of PharmaCyte Biotech Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
SEKUR PRIVATE DATA LTD.
F:GDT0
|
$4.55 Million |
|
Ho Hup Construction Company
KLSE:5169
|
$4.55 Million |
|
Project Planning Service Public Company Limited
BK:PPS
|
$4.56 Million |
|
Krakatoa Resources Ltd
AU:KTA
|
$4.56 Million |
|
Magic Empire Global Limited
NASDAQ:MEGL
|
$4.55 Million |
|
BIRD RIVER RES. INC.
F:1Q1A
|
$4.55 Million |
|
GB Group plc
LSE:GBG
|
$4.54 Million |
|
Azucar Minerals Ltd
V:AMZ
|
$4.54 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in PharmaCyte Biotech Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2025 to 2026, total equity changed from 51,891,069 to 33,294,926, a change of -18,596,143 (-35.8%).
- Net loss of 19,424,654 reduced equity.
- Dividend payments of 246,005 reduced retained earnings.
- Share repurchases of 401,625 reduced equity.
- New share issuances of 6,182,447 increased equity.
- Other comprehensive income increased equity by 3,073.
- Other factors decreased equity by 4,709,379.
Equity Change Factors (2025 to 2026)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-19.42 Million | -58.34% |
| Dividends Paid | $246.00K | -0.74% |
| Share Repurchases | $401.62K | -1.21% |
| Share Issuances | $6.18 Million | +18.57% |
| Other Comprehensive Income | $3.07K | +0.01% |
| Other Changes | $-4.71 Million | -14.14% |
| Total Change | $- | -35.84% |
Book Value vs Market Value Analysis
This analysis compares PharmaCyte Biotech Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.11x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2002-04-30 | $-0.13 | $0.42 | x |
| 2003-04-30 | $-0.04 | $0.42 | x |
| 2004-04-30 | $-2.44 | $0.42 | x |
| 2005-04-30 | $-18.70 | $0.42 | x |
| 2006-04-30 | $48.40 | $0.42 | x |
| 2007-04-30 | $39.56 | $0.42 | x |
| 2008-04-30 | $66.39 | $0.42 | x |
| 2009-04-30 | $20.55 | $0.42 | x |
| 2010-04-30 | $-8.33 | $0.42 | x |
| 2011-04-30 | $-11.68 | $0.42 | x |
| 2012-04-30 | $-6.80 | $0.42 | x |
| 2013-04-30 | $-3.13 | $0.42 | x |
| 2014-04-30 | $22.99 | $0.42 | x |
| 2015-04-30 | $12.64 | $0.42 | x |
| 2016-04-30 | $13.00 | $0.42 | x |
| 2017-04-30 | $14.34 | $0.42 | x |
| 2018-04-30 | $0.01 | $0.42 | x |
| 2019-04-30 | $0.00 | $0.42 | x |
| 2020-04-30 | $0.00 | $0.42 | x |
| 2021-04-30 | $0.00 | $0.42 | x |
| 2022-04-30 | $17.37 | $0.42 | x |
| 2023-04-30 | $14.04 | $0.42 | x |
| 2024-04-30 | $4.12 | $0.42 | x |
| 2025-04-30 | $7.08 | $0.42 | x |
| 2026-04-30 | $3.97 | $0.42 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently PharmaCyte Biotech Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -58.34%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.40x
- Recent ROE (-58.34%) is above the historical average (-60.54%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2002 | 0.00% | 0.00% | 0.00x | 0.00x | $-29.06K |
| 2003 | 0.00% | 0.00% | 0.00x | 0.00x | $-31.88K |
| 2004 | 0.00% | -72375.79% | 0.01x | 0.00x | $-1.71 Million |
| 2005 | 0.00% | -4951.60% | 0.26x | 0.00x | $-4.15 Million |
| 2006 | -212.72% | -1747.55% | 0.10x | 1.16x | $-9.83 Million |
| 2007 | -84.32% | -308.89% | 0.27x | 1.03x | $-4.04 Million |
| 2008 | -51.00% | -318.66% | 0.16x | 1.02x | $-4.54 Million |
| 2009 | -193.44% | -925.08% | 0.11x | 1.93x | $-6.35 Million |
| 2010 | 0.00% | -2278.89% | 0.22x | 0.00x | $-5.80 Million |
| 2011 | 0.00% | -1109.55% | 0.10x | 0.00x | $-1.13 Million |
| 2012 | 0.00% | -2853.15% | 0.03x | 0.00x | $-1.73 Million |
| 2013 | 0.00% | -13141.45% | 0.00x | 0.00x | $-1.51 Million |
| 2014 | -304.77% | 0.00% | 0.00x | 1.04x | $-28.15 Million |
| 2015 | -182.87% | 0.00% | 0.00x | 1.34x | $-11.45 Million |
| 2016 | -92.96% | 0.00% | 0.00x | 1.10x | $-6.72 Million |
| 2017 | -54.95% | 0.00% | 0.00x | 1.07x | $-5.25 Million |
| 2018 | -118.38% | 0.00% | 0.00x | 1.11x | $-7.41 Million |
| 2019 | -80.71% | 0.00% | 0.00x | 1.15x | $-4.57 Million |
| 2020 | -75.21% | 0.00% | 0.00x | 1.21x | $-4.34 Million |
| 2021 | -53.21% | 0.00% | 0.00x | 1.11x | $-4.22 Million |
| 2022 | -4.71% | 0.00% | 0.00x | 1.01x | $-13.23 Million |
| 2023 | -5.94% | 0.00% | 0.00x | 1.01x | $-11.59 Million |
| 2024 | 0.84% | 0.00% | 0.00x | 1.52x | $-3.62 Million |
| 2025 | 59.08% | 0.00% | 0.00x | 1.06x | $25.47 Million |
| 2026 | -58.34% | 0.00% | 0.00x | 1.40x | $-22.75 Million |
Industry Comparison
This section compares PharmaCyte Biotech Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $249,490,347
- Average return on equity (ROE) among peers: -108.27%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| PharmaCyte Biotech Inc (PMCB) | $34.98 Million | 0.00% | 0.34x | $4.55 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $120.41 Million |
| Abcellera Biologics Inc (ABCL) | $1.06 Billion | -15.42% | 0.29x | $2.99 Billion |
| Abeona Therapeutics Inc (ABEO) | $1.80 Million | -188.89% | 0.33x | $307.08 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-18.59 Million | 0.00% | 0.00x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $1.57 Billion |
| Arbutus Biopharma Corp (ABUS) | $101.97 Million | -62.52% | 0.34x | $906.70 Million |
| ABVC Biopharma Inc (ABVC) | $1.25 Million | -621.32% | 5.21x | $28.25 Million |
| Abivax SA American Depositary Shares (ABVX) | $25.93 Million | -163.70% | 3.21x | $9.34 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $1.23 Billion | 31.86% | 0.27x | $4.73 Billion |
About PharmaCyte Biotech Inc
PharmaCyte Biotech, Inc., a biotechnology company, focused on developing and preparing to commercialize cellular therapies for cancer using live cell encapsulation technology in the United States. The company's cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including adv… Read more